




### LISTING OF CLAIMS

17. (PREVIOUSLY PRESENTED) A pharmaceutical composition for treatment of obesity associated with lipid and carbohydrate metabolism comprising (i) a substance which is useful in promoting lipid and carbohydrate metabolism, (ii) an antioxidant agent and, optionally, (iii) a pharmaceutically acceptable carrier or excipient, wherein the substance which promotes lipid and carbohydrate metabolism and the antioxidant agent are present in therapeutically effective dosages.

5

10

18. (PREVIOUSLY PRESENTED) The composition of Claim 17, wherein the substance which promotes lipid and carbohydrate metabolism is a compound selected from those of formula (I) :



wherein :

- X represents an oxygen or sulphur atom, or a group  $\text{CH}_2$  or  $\text{CH}$ , wherein  $\text{R}^2$  together with  $\text{R}^2$  forms an additional bond,
- $\text{R}^1$  and  $\text{R}^2$ , which may be the same or different, each represent a hydrogen atom, a linear or branched  $(\text{C}_1\text{-C}_6)$ alkyl group, an aryl group, an aryl- $(\text{C}_1\text{-C}_6)$ alkyl group in which the alkyl moiety is linear or branched, an aryloxy group, an aryl- $(\text{C}_1\text{-C}_6)$ alkoxy group in which the alkyl moiety is linear or branched, a linear or branched  $(\text{C}_1\text{-C}_6)$ alkoxy group, a hydroxy group, an amino group, a linear or branched

15

(C<sub>1</sub>-C<sub>6</sub>)alkylamino group or a di-(C<sub>1</sub>-C<sub>6</sub>)alkylamino group in which the alkyl moieties are linear or branched,

or R<sup>1</sup> and R<sup>2</sup> together form an oxo, thioxo or imino group,

it also being possible for R<sup>2</sup> together with R<sup>2</sup> to form an additional bond,

- 5       • A represents a (C<sub>1</sub>-C<sub>6</sub>)alkylene chain in which one CH<sub>2</sub> group may be replaced by a hetero atom selected from oxygen and sulphur or by a group NR<sub>a</sub>, wherein R<sub>a</sub> represents a hydrogen atom or a linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl group, or by a phenylene or naphthylene group,
- 10       • R<sup>3</sup> and R<sup>4</sup>, which may be the same or different, each represent a hydrogen or halogen atom or a group R, OR or NRR', wherein R and R', which may be the same or different, each represent a hydrogen atom or a linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl group, a linear or branched (C<sub>2</sub>-C<sub>6</sub>)alkenyl group, a linear or branched (C<sub>2</sub>-C<sub>6</sub>)alkynyl group, an aryl group, an aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl group in which the alkyl moiety is linear or branched, an aryl-(C<sub>2</sub>-C<sub>6</sub>)alkenyl group in which the alkenyl moiety is linear or branched, an
- 15       aryl-(C<sub>2</sub>-C<sub>6</sub>)alkynyl group in which the alkynyl moiety is linear or branched, a heteroaryl group, a heteroaryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl group in which the alkyl moiety is linear or branched, a heteroaryl-(C<sub>2</sub>-C<sub>6</sub>)alkenyl group in which the alkenyl moiety is linear or branched, a heteroaryl-(C<sub>2</sub>-C<sub>6</sub>)alkynyl group in which the alkynyl moiety is linear or branched, a (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl group, a (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl-(C<sub>1</sub>-C<sub>6</sub>)alkyl group in which
- 20       the alkyl moiety is linear or branched, or a linear or branched (C<sub>1</sub>-C<sub>6</sub>)polyhaloalkyl group,
- or R<sup>3</sup> and R<sup>4</sup>, together with the carbon atoms carrying them, when they are carried by two adjacent carbon atoms, form a ring that has 5 or 6 ring members and that may contain a hetero atom selected from oxygen, sulphur and nitrogen,
- 25       • R<sup>5</sup> and R<sup>6</sup>, which may be the same or different, each represent a hydrogen atom or a linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl group, a linear or branched (C<sub>2</sub>-C<sub>6</sub>)alkenyl group, a linear or branched (C<sub>2</sub>-C<sub>6</sub>)alkynyl group, an aryl group, an aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl group in which the alkyl moiety is linear or branched, an aryl-(C<sub>2</sub>-C<sub>6</sub>)alkenyl group in which

the alkenyl moiety is linear or branched, an aryl-(C<sub>2</sub>-C<sub>6</sub>)alkynyl group in which the alkynyl moiety is linear or branched, a heteroaryl group, a heteroaryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl group in which the alkyl moiety is linear or branched, a heteroaryl-(C<sub>2</sub>-C<sub>6</sub>)alkenyl group in which the alkenyl moiety is linear or branched, a heteroaryl-(C<sub>2</sub>-C<sub>6</sub>)alkynyl group in which the alkynyl moiety is linear or branched, a (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl group, a (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl-(C<sub>1</sub>-C<sub>6</sub>)alkyl group in which the alkyl moiety is linear or branched, or a linear or branched (C<sub>1</sub>-C<sub>6</sub>)polyhaloalkyl group,


- D represents:

a benzene nucleus, in which case X cannot represent a group  $\begin{array}{c} R^{12} \\ | \\ CH \end{array}$

or D represents a pyridine, pyrazine, pyrimidine or pyridazine nucleus,

- B represents a linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl group or a linear or branched (C<sub>2</sub>-C<sub>6</sub>)-alkenyl group, those groups being substituted :

- ♦ by a group of formula (II) :




wherein :

- R<sup>7</sup> represents a group  $\begin{array}{c} Z \\ || \\ -C-OR \end{array}$  ,  $\begin{array}{c} Z \\ || \\ -C-NRR' \end{array}$  ,  $\begin{array}{c} Z \\ || \\ -N(R)C-R' \end{array}$

or  $\begin{array}{c} Z \\ || \\ -N(R)C-OR' \end{array}$  ,


wherein Z represents an oxygen or sulphur atom,

- and  $R^8$  represents an aryl group, an arylalkyl group wherein the alkyl moiety contains from 1 to 6 carbon atoms and may be linear or branched, a heteroaryl group, a heteroarylalkyl group wherein the alkyl moiety contains from 1 to 6 carbon atoms and may be linear or branched, CN, tetrazole,  $—OR$  ,  $—NRR'$  ,



5

♦ or by a group  $R^9$ , wherein  $R^9$  represents a CN, tetrazole,



wherein n represents 0, 1, 2, 3, 4, 5 or 6, and  $R^{10}$  and  $R^{11}$ , which may be the same or different, each represent a hydrogen atom or a linear or branched ( $C_1$ - $C_6$ )alkyl group, it being understood that  $R^{10}$  and  $R^{11}$  cannot simultaneously represent a hydrogen atom,

10 or B represents a group of formula (II) or a group  $R^9$ ,

it being understood that :

- \* the oxime  $R^6-C(=N-OR^5)-$  can be of Z or E configuration,
- \* aryl means a phenyl, naphthyl or biphenyl group, it being possible for those groups to be partially hydrogenated,
- 15 \* heteroaryl means any mono- or bi-cyclic aromatic group containing 5 to 10 members, which may be partially hydrogenated in one of the rings in the case of bicyclic heteroaryls and which contains 1 to 3 hetero atoms selected from oxygen, nitrogen and sulphur,

wherein the aryl and heteroaryl groups may be optionally substituted by from 1 to 3 groups selected from linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl, linear or branched (C<sub>1</sub>-C<sub>6</sub>)polyhaloalkyl, linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkoxy, hydroxy, carboxy, formyl, NR<sub>b</sub>R<sub>c</sub>, wherein R<sub>b</sub> and R<sub>c</sub>, which may be the same or different, each represent a hydrogen atom, a linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl group, an aryl group or a heteroaryl group, ester, amido, nitro, cyano, and halogen atoms,

its enantiomers and diastereoisomers thereof, and addition salts thereof with a pharmaceutically acceptable acid or base.

19. (PREVIOUSLY PRESENTED) The composition of Claim 1, wherein the substance which promotes lipid and carbohydrate metabolism is 2-ethoxy-3-{4-[2-(6-[(hydroxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2H)-yl)ethoxy]phenyl}propanoic acid, its enantiomers and diastereoisomers thereof, and addition salts thereof with a pharmaceutically acceptable acid or base.

20. (PREVIOUSLY PRESENTED) The composition of Claim 17, wherein the antioxidant agent is coenzyme Q<sub>10</sub>.

21. (PREVIOUSLY PRESENTED) The composition of Claim 17, wherein the antioxidant agent is vitamin E.

22. (PREVIOUSLY PRESENTED) The composition of Claim 17, which is 2-ethoxy-3-{4-[2-(6-[(hydroxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2H)-yl)ethoxy]phenyl}propanoic acid and coenzyme Q<sub>10</sub>.

23. (PREVIOUSLY PRESENTED) The composition of Claim 17, which is 2-ethoxy-3-{4-[2-(6-[(hydroxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2H)-yl)ethoxy]phenyl}propanoic acid and vitamin E.

24. (PREVIOUSLY PRESENTED) A method for treating a living animal body, including a human, afflicted with obesity, comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 17 which is effective for alleviation of obesity.

5 25. (PREVIOUSLY PRESENTED) A method for treating a living animal body, including a human, afflicted with obesity caused by a therapeutic treatment, comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 17 which is effective for alleviation of obesity caused by a therapeutic treatment.

10 26. (PREVIOUSLY PRESENTED) A method for treating a living animal body, including a human, afflicted with obesity caused by treatment for type I or II diabetes, comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 17 which is effective for alleviation of obesity caused by treatment for type I or II diabetes.

15 27. (CURRENTLY AMENDED) A method for treating a living animal body, including a human, afflicted with ~~obesity~~ overweight characterised by a body mass index greater than 25 and less than 30, comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 17 which is effective  
20 for alleviation of ~~obesity~~ overweight characterised by a body mass index greater than 25 and less than 30.

25 28. (CURRENTLY AMENDED) A method for treating a living animal body, including a human, afflicted with ~~obesity~~ overweight characterised by a body mass index greater than 25 and less than 30 caused by a therapeutic treatment, comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 17 which is effective for alleviation of ~~obesity~~ overweight

characterised by a body mass index greater than 25 and less than 30 caused by a therapeutic treatment.

- 5 29. (CURRENTLY AMENDED) A method for treating a living animal body, including a human, afflicted with ~~obesity~~ overweight characterised by a body mass index greater than 25 and less than 30 caused by treatment for type I or II, diabetes comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 17 which is effective for alleviation of ~~obesity~~ overweight characterised by a body mass index greater than 25 and less than 30 caused by treatment for type I or II diabetes.